Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 11/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | MTOR | P42345 | 1/20 | 0.53 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.53 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.53 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.53 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.52 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.52 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.52 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.52 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | CDA | P32320 | 1/20 | 0.47 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6803564 | 1.00 | P2RY2 (0.64) | P2RY2LMNATHRBMTORMDM2 | |
| SCHEMBL6913363 | 0.88 | P2RY2 (0.69) | P2RY2LMNATHRBMTORMDM2 | |
| SCHEMBL6913372 | 0.88 | P2RY2 (0.69) | P2RY2LMNATHRBMTORMDM2 | |
| SCHEMBL6797262 | 0.88 | P2RY2 (0.64) | P2RY2LMNATHRBMTORMDM2 | |
| SCHEMBL6797260 | 0.88 | P2RY2 (0.64) | P2RY2LMNATHRBMTORMDM2 | |
| SCHEMBL6797619 | 0.87 | P2RY2 (0.52) | P2RY2LMNATHRBMTORMDM2 | |
| SCHEMBL6797612 | 0.87 | P2RY2 (0.52) | P2RY2LMNATHRBMTORMDM2 | |
| SCHEMBL6797624 | 0.85 | P2RY2 (0.64) | P2RY2LMNATHRBMTORMDM2 | |
| SCHEMBL6797626 | 0.85 | P2RY2 (0.64) | P2RY2LMNATHRBMTORMDM2 | |
| Phosphoric Acid SCHEMBL6803088 | 0.84 | P2RY2 (0.68) | P2RY2LMNATHRBMTORMDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040122223-A1 | Non-natural nucleotides and dinucleotides | CELLTECH R & D LIMITED (GB) | 2004-06-24 | — | — | US | disclosed |
| EP-1368366-A1 | NON-NATURAL NUCLEOTIDES AND DINUCLEOTIDES | Celltech R & D Limited (GB) | 2003-12-10 | — | — | EP | disclosed |
| WO-2002062816-A1 | NON-NATURAL NUCLEOTIDES AND DINUCLEOTIDES | CELLTECH R & D LIMITED (GB) | 2002-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122223-A1 | Non-natural nucleotides and dinucleotides | P2RY1, P2RY11, P2RY13 | P2RY2 8/4885LMNA 3439/4885THRB 1853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.